Symbio Cell Tech
Biotechnology, 615 S Arapeen Dr, Salt Lake City, Utah, 84108, United States, 1-10 Employees
Phone Number: +18*********
Who is SYMBIOCELLTECH
SymbioCellTech (SCT) is an early stage, university spin out, that has developed stem cell-based technology that achieves euglycemia (glucose control) in Type-1 Diabetes, and will soon be ...
Read More
- Headquarters: 615 S Arapeen Dr, Salt Lake City, Utah, 84108, United States
- Date Founded: 2014
- Employees: 1-10
- Revenue: Under $1 Million
- Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
Does something look wrong? Fix it. | View contact records from SYMBIOCELLTECH
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding SymbioCellTech
Answer: SymbioCellTech's headquarters are located at 615 S Arapeen Dr, Salt Lake City, Utah, 84108, United States
Answer: SymbioCellTech's phone number is +18*********
Answer: SymbioCellTech's official website is https://symbiocelltech.com
Answer: SymbioCellTech's revenue is Under $1 Million
Answer: SymbioCellTech's SIC: 8731
Answer: SymbioCellTech has 1-10 employees
Answer: SymbioCellTech is in Biotechnology
Answer: SymbioCellTech contact info: Phone number: +18********* Website: https://symbiocelltech.com
Answer: SymbioCellTech (SCT) is an early stage, university spin out, that has developed stem cell-based technology that achieves euglycemia (glucose control) in Type-1 Diabetes, and will soon be adapted for Type-2 Diabetes. The SCT proprietary Neo-Iset therapy, comprising both pancreatic islet and mesenchymal stem cells, can be administered in a simple out-patient procedure resulting in glucose control identical to that of a normal healthy individual. Backed by rigorous NIH, VA and privately funded research and resultant data, SCT has completed pre-clinical trials and is preparing for FDA submission and approval to begin well-designed, controlled, clinical trials treating humans suffering from Type-1 Diabetes. FDA Investigational New Animal Drug (INAD) approval for diabetic companion animals has been approved and canine clinical trials are ongoing with outstanding results and outcomes.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month